Dec 07, 2022 / NTS GMT
Gary Jay Nachman - BMO Capital Markets Equity Research - Senior BioPharma Analyst
Hi, everyone. I'm Gary Nachman, a senior biopharma analyst at BMO, and we're really excited to have Ionis management participating with us in BMO's Growth and ESG Conference. We have Eugene Schneider, Head of Clinical Development; and Roslyn Patterson, VP of Marketing and Communications.
Ionis has a great platform in RNA-targeted antisense technology with a very robust portfolio across cardiovascular disease and neurology. And the company recently announced a deal with Metagenomi, expanding its capabilities into gene editing. So a lot of exciting programs in the pipeline that we'll be able to cover, and it's great to have you guys here to discuss that with us. So thank you for being here.
Eugene Schneider - Ionis Pharmaceuticals, Inc. - Executive VP & Chief Clinical Development Officer
Thank you, Gary, for having us.
Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers